Providing patient access support for OGIVRI

Your VIATRIS ADVOCATE^® team is here for you

VIATRIS^™ commitment also extends to patient access support through VIATRIS ADVOCATE, where a team of dedicated patient access specialists is available to answer calls and address questions you and your providers may have regarding:

Insurance coverage verification and out of pocket costs

Check patient insurance plan coverage status.
Determine the patient’s deductible and out-of-pocket costs.

Patient Assistance

Patients without insurance coverage for OGIVRI who cannot afford their medication may be able to receive their medication free of charge.
Eligibility requirements apply based on residency, income, and other factors. Contact Viatris Advocate for more information.

Copay Assistance

Commercially insured patients may be able to access Ogivri for as low as a $0 copay.*
There are no income restrictions

*Certain limits and restrictions apply. Please see eligibility criteria and terms and conditions below

Alternate Coverage Identification

Viatris Advocate can help identify other resources, such as state programs or third-party charitable foundations, that may be able to assist you.

CO-PAY TERMS AND CONDITIONS

The VIATRIS ADVOCATE Co-Pay Assistance Program for OGIVRI (trastuzumab-dkst) for injection 150 mg/vial and/or 420 mg/vials open to both new and existing eligible patients who have commercial prescription drug insurance.

This co-pay assistance can be redeemed by patients or patient guardians who are residents of the U.S. or Puerto Rico and who are 18 years of age or older, subject to the full terms and conditions set forth on VIATRIS^™ website as it may be updated from time to time - www.VIATRISADVOCATE.com. This co-pay assistance program can be used to reduce the amount of an eligible patient’s out-of-pocket expenses for VIATRIS^™ OGIVRI (trastuzumab-dkst) for injection 150 mg/vial and/or 420 mg/vial up to the maximum aggregate amount set forth on VIATRIS^™ website while this co-pay assistance program remains in effect (such aggregate amount includes dispenses of both OGIVRI (trastuzumab-dkst) for injection 150 mg/vial and 420 mg/vial).

This co-pay assistance program is not valid for uninsured patients or commercially insured patients without coverage for OGIVRI (trastuzumab-dkst) for injection 150 mg/vial and/or 420 mg/vial; not valid for patients who are covered in whole or in part by any state or federally funded healthcare program, including, but not limited to, any state pharmaceutical assistance program, Medicare (Part D or otherwise), Medicaid, Medigap, VA or DOD, or TriCare (regardless of whether OGIVRI (trastuzumab-dkst) for injection 150 mg/vial and/or 420 mg/vial is covered by such government program); not valid if the patient is Medicare eligible and enrolled in an employer-sponsored health plan or prescription beneﬁt program for retirees; and not valid if the patient’s insurance plan is paying the entire cost of this prescription. This co-pay assistance program is void outside the U.S. or Puerto Rico or in any state or jurisdiction where prohibited by law, taxed or restricted. Absent a change in Massachusetts law, this co-pay assistance program will no longer be valid for Massachusetts residents as of January 1, 2023. Please see VIATRIS^™ website for any updates.

Valid prescription required. Use of this co-pay assistance program must be consistent with the terms of any drug beneﬁt provided by a commercial health insurer, health plan or private third-party payer. This co-pay assistance program may be changed or discontinued at any time without notice. This co-pay assistance program is not health insurance. The co-pay assistance program is not transferable, and the amount of the savings cannot exceed the patient’s out-of-pocket expenses. Cannot be combined with any other rebate/coupon, free trial, or similar offer for the speciﬁed prescription. The co-pay assistance is not redeemable for cash. No additional purchase is required. Data related to your use of this co-pay assistance program may be collected, analyzed and shared with Viatris for market research and other purposes related to assessing copay assistance programs. Data shared with Viatris will be aggregated and de-identiﬁed, meaning it will be combined with data related to other co-pay assistance program redemptions and will not identify you.